Yes, Lantus is a long-acting basal insulin.
Lantus (insulin glargine) is definitively classified as a long-acting basal insulin with a duration of action up to 24 hours, designed to provide steady background insulin coverage without a pronounced peak 1.
Pharmacologic Profile
Lantus has distinct pharmacodynamic characteristics that define it as long-acting:
The peakless action profile is achieved through a unique mechanism: after subcutaneous injection, the acidic solution (pH ~4) is neutralized in tissue, forming microprecipitates that slowly release insulin glargine, resulting in relatively constant insulin levels over 24 hours 1.
Clinical Classification and Use
Lantus is specifically indicated as basal insulin for once-daily administration 1. Guidelines consistently categorize it as long-acting insulin used for basal coverage 2, 5, 6. It is recommended for:
- Type 1 diabetes: As part of basal-bolus regimens, typically 16-24 units once daily at bedtime 2
- Type 2 diabetes: As initial insulin therapy or intensification of oral agents 5, 6, 1
The medication slowly releases insulin over 24 hours to maintain physiologic basal insulin levels, controlling fasting glucose and hepatic glucose production between meals and overnight 2, 5.
Advantages Over Intermediate-Acting Insulin
Glargine is absorbed more consistently than intermediate-acting insulins (NPH) and reduces hypoglycemia risk 2. Studies demonstrate symptomatic hypoglycemia was less common with glargine (39.9% vs 49.2% with NPH, p=0.02) 2, with particularly significant reductions in nocturnal hypoglycemia 7, 8, 9.
Key Clinical Considerations
- Glargine cannot be mixed with other insulins due to its acidic pH
- It is administered subcutaneously once daily, typically at bedtime, though timing can be adjusted 4
- In some patients, the duration may be less than 24 hours, requiring twice-daily dosing 4
- It is approved for pediatric patients ≥6 years of age 4, 1
Human NPH insulin remains a less expensive alternative, though with modestly higher hypoglycemia risk 5, 6.